BioCentury | Apr 7, 2014
Regulation

Confirming endpoints

...Phase II study in Japan using pain as the primary endpoint. According to its website, Switch Biotech...
...National Fibromyalgia & Chronic Pain Association (NFMCPA), Logan, Utah Pfizer Inc. (NYSE:PFE), New York, N.Y. Switch Biotech...
BioCentury | Sep 19, 2005
Company News

Biofrontera, Switch Biotech deal

...said the compound is marketed for indications outside of dermatology. Biofrontera AG , Leverkusen, Germany Switch Biotech AG...
BioCentury | Jul 26, 2004
Company News

Immuno-Designed Molecules SA board of directors update

...SA , Paris, France Business: Cancer Appointed: Marc Guyader, director of INSEAD and chairman of Switch Biotech AG WIR...
BioCentury | Apr 12, 2004
Company News

Switch Biotech, Spirig Pharma AG deal

...that is inhibited in vitiligo patients' melanocytes. The partners will share rights to any products. Switch Biotech AG...
BioCentury | Oct 27, 2003
Company News

Switch Biotech management update

Switch Biotech AG , Neuried, Germany Business: Dermatology Promoted: Stefan Schulze to CEO from CFO WIR Staff Dermatology...
BioCentury | Jun 2, 2003
Product Development

Switching drugs to the skin

...To get to market faster, German dermatology play Switch Biotech AG is profiling drugs that have been approved...
BioCentury | Jun 2, 2003
Clinical News

SWT01: Phase I

...Switch started a double-blind, placebo-controlled German Phase I study in 42 patients. Switch Biotech AG , Neuried, Germany...
BioCentury | Mar 31, 2003
Company News

Switch Biotech management update

Switch Biotech AG , Neuried, Germany Business: Biomaterial/Skin/Wound, Dermatology Hired: Erwin Bohm as chief development officer, formerly head of clinical development at MediGene AG WIR Staff Dermatology...
BioCentury | Feb 17, 2003
Company News

Switch Biotech, Ludwig Maximilian University deal

...proliferation. Switch plans to use the target to develop therapeutics for skin diseases, including psoriasis. Switch Biotech AG...
BioCentury | Feb 17, 2003
Company News

Leo Pharma, Switch Biotech deal

...can aid in the development of drugs to treat psoriasis. Leo Pharma , Copenhagen, Denmark Switch Biotech AG...
Items per page:
1 - 10 of 24
BioCentury | Apr 7, 2014
Regulation

Confirming endpoints

...Phase II study in Japan using pain as the primary endpoint. According to its website, Switch Biotech...
...National Fibromyalgia & Chronic Pain Association (NFMCPA), Logan, Utah Pfizer Inc. (NYSE:PFE), New York, N.Y. Switch Biotech...
BioCentury | Sep 19, 2005
Company News

Biofrontera, Switch Biotech deal

...said the compound is marketed for indications outside of dermatology. Biofrontera AG , Leverkusen, Germany Switch Biotech AG...
BioCentury | Jul 26, 2004
Company News

Immuno-Designed Molecules SA board of directors update

...SA , Paris, France Business: Cancer Appointed: Marc Guyader, director of INSEAD and chairman of Switch Biotech AG WIR...
BioCentury | Apr 12, 2004
Company News

Switch Biotech, Spirig Pharma AG deal

...that is inhibited in vitiligo patients' melanocytes. The partners will share rights to any products. Switch Biotech AG...
BioCentury | Oct 27, 2003
Company News

Switch Biotech management update

Switch Biotech AG , Neuried, Germany Business: Dermatology Promoted: Stefan Schulze to CEO from CFO WIR Staff Dermatology...
BioCentury | Jun 2, 2003
Product Development

Switching drugs to the skin

...To get to market faster, German dermatology play Switch Biotech AG is profiling drugs that have been approved...
BioCentury | Jun 2, 2003
Clinical News

SWT01: Phase I

...Switch started a double-blind, placebo-controlled German Phase I study in 42 patients. Switch Biotech AG , Neuried, Germany...
BioCentury | Mar 31, 2003
Company News

Switch Biotech management update

Switch Biotech AG , Neuried, Germany Business: Biomaterial/Skin/Wound, Dermatology Hired: Erwin Bohm as chief development officer, formerly head of clinical development at MediGene AG WIR Staff Dermatology...
BioCentury | Feb 17, 2003
Company News

Switch Biotech, Ludwig Maximilian University deal

...proliferation. Switch plans to use the target to develop therapeutics for skin diseases, including psoriasis. Switch Biotech AG...
BioCentury | Feb 17, 2003
Company News

Leo Pharma, Switch Biotech deal

...can aid in the development of drugs to treat psoriasis. Leo Pharma , Copenhagen, Denmark Switch Biotech AG...
Items per page:
1 - 10 of 24